National Cancer Institute (NCI) Awards Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant
BALTIMORE, Sept. 7, 2021 /PRNewswire/ — Isoprene Pharmaceuticals, Inc., an early-stage small molecule oncology company developing oral therapeutics for triple negative breast cancer (TNBC) and other cancers, today announced that the National Institute of Health’s (NIH) NCI has awarded the company a two-year $2 million Small Business Innovation Research (SBIR) Direct-to-Phase II grant. This grant will support ongoing advanced pre-clinical studies intended to lead to the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA), as a prelude to Phase I clinical trials. Vidya P. Ramamurthy, PhD, Isoprene’s chief scientific officer, and Vincent C. O. Njar, PhD, co-founder and chief executive officer of Isoprene and Professor at the University of Maryland School of Medicine (UMSOM), are the principal investigators for the program.
“Currently, there are no effective therapies for patients with TNBC, an aggressive and highly metastatic disease. Isoprene’s orally dosed novel small molecules function as protein degraders, breaking down protein kinases Mnk1/2,” stated Rana Quraishi, PhD, chief business officer of Isoprene and director of UMB’s New Ventures Initiative. “In TNBC xenograft models, the molecules have been shown to result in remarkable dose-dependent anti-tumor activity with no apparent host toxicity.”
Isoprene’s orally bioavailable lead molecule exhibits remarkable dose-dependent antitumor (91% to 100% growth inhibition) and antimetastatic (~80% inhibition) activities against cell line and patient-derived TNBC xenograft models. Collectively, these studies demonstrate that targeting Mnk-eIF4E/mTORC1 signaling with a potent Mnk1/2 degrader is a novel therapeutic strategy that can be developed as monotherapy for the effective treatment of patients with both primary and metastatic TNBC.
“By targeting Mnk1/2 protein degradation, our molecules potently inhibit two critical signaling pathways and strongly regulate downstream factors involved in cell cycle regulation, cell death (apoptosis), pro-inflammatory cytokines/chemokines secretion, epithelial-mesenchymal transition (EMT) and metastasis,” said Dr. Njar. “This plays a critical role in the development, progression and metastasis of TNBC. Mnk1/2 are particularly attractive therapeutic targets because Mnk1/2 activity and the phosphorylation of eIF4E are dispensable for normal development.”
Dr. Njar’s laboratory developed Isoprene’s novel small molecule technology at the UMSOM where he is a long-standing faculty member with primary faculty appointments in the Department of Pharmacology and the Center for Biomolecular Therapeutics.
Margaret M. McCarthy, PhD, professor and chair of the Department of Pharmacology, commented, “This is another in a long line of successes for Dr. Njar. His dedication and devotion to the creation and implementation of life-saving cancer therapeutics is beyond measure. We can all celebrate this important affirmation from the NIH of the potential impact of the newly developed retinoic acid metabolism blocking agents (RAMBAs)/Mnk1/2 protein degraders.”
David J. Weber, PhD, professor and director of the Center for Biomolecular Therapeutics, added, “Dr. Njar’s research and development involving RAMBAs/Mnk1/2 protein degraders is extremely exciting for treatment of cancer and other diseases, and this recently funded fast-track NIH/NCI Award will significantly accelerate the ‘bench to bedside’ research required to get these novel therapeutic agents to patients.”
Isoprene is part of UMB’s New Ventures Initiative (NVI) program, a unique model for select UMB startups with significant commercial promise. The NVI program accelerates research and startup growth, positioning companies for a strategic exit. Managed by an expert team with executive-level experience developing and executing business strategies, raising private and public capital, and taking drugs through Phase II clinical trials, NVI portfolio companies benefit from full management, business formation strategy, office space and a fully equipped laboratory space, along with direct access to early-stage capital. Since the program was established in 2015, the NVI team has fully managed and exited two startups: Living Pharma, which was acquired by Miltenyi, and SurgiGYN, which was acquired by a large medical device company. Isoprene is the third NVI portfolio company.
“We are very impressed with Isoprene’s progress,” said Phil Robilotto, DO, MBA, associate vice president of UMB’s Office of Technology Transfer and director of UM Ventures at Baltimore. “The NVI program helps our startups advance faster and is a critical tool for commercializing UMB’s most promising technologies. We continue to be pleased with the program’s track record.”
About Isoprene Pharmaceuticals, Inc.
Isoprene Pharmaceuticals, Inc. is focused on oncology applications of the novel small molecule Mnk1/2 protein degraders developed by co-founder and chief executive officer Vincent C. O. Njar, PhD. While oncology is the first indication, these Mnk1/2 protein degraders have additional applications in oncology, dermatology, inflammatory bowel disorders (IBDs) and other diseases. Isoprene has partnered with Hoth Therapeutics to develop the dermatology and IBD indications.
In addition to his role with Isoprene, Dr. Njar, an inaugural Distinguished University Professor at UMB, holds multiple appointments in the University of Maryland School of Medicine: Professor of Medicinal Chemistry and Pharmacology in the Department of Pharmacology; Head of the Medicinal Chemistry Section in the Center for Biomolecular Therapeutics (CBT); and Fellow in the Institute for Biosciences and Biotechnology Research (IBBR). As a UMB NVI portfolio company, Isoprene is co-led by Rana Quraishi, PhD, director of the NVI. Dr. Quraishi manages all business and strategic planning for Isoprene along with the New Ventures team. Isoprene’s offices and lab are located in the University of Maryland BioPark.
About the University of Maryland, Baltimore and UM Ventures
The University of Maryland, Baltimore (UMB) is a fast-growing biomedical research center with nationally ranked professional schools of dentistry, law, medicine, nursing, pharmacy, social work, and an interdisciplinary graduate school. UM Ventures commercializes UMB’s breakthrough therapies, diagnostics and devices, fuels the creation of innovative start-up companies, and attracts industry leaders and entrepreneurs to the University’s thriving downtown campus. A wide portfolio of technologies is available for licensing at www.umventures.org.
SOURCE University of Maryland Ventures
Latest posts by BioBuzz Media (see all)
- NIH launches first phase of $9.8 million competition to accelerate development of neuromodulation therapies - January 19, 2022
- The Center for Breakthrough Medicines and the University of Pennsylvania Partner in the Manufacturing of Gene Therapies - January 19, 2022
- Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology - January 19, 2022
- Suzy Turman Joins Workforce Genetics as a Senior Life Science Talent Consultant - January 18, 2022
- Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences - January 18, 2022